Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8476589 | Molecular and Cellular Endocrinology | 2018 | 24 Pages |
Abstract
The present findings show that MAMs are severely reduced in animal models of glucose intolerance, which reinforces the role of MAMs as a hub for insulin signaling in the liver. We also show that SFN restores MAMs and improves glucose tolerance by a similar magnitude to that of metformin. These data highlight SFN as a new potential anti-diabetic compound.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Emily Tubbs, Annika S. Axelsson, Guillaume Vial, Claes B. Wollheim, Jennifer Rieusset, Anders H. Rosengren,